期刊
IMMUNOTHERAPY
卷 9, 期 6, 页码 467-470出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2016-0119
关键词
cervical squamous carcinoma; immuno-oncology; pembrolizumab PD-1 inhibitors
类别
资金
- Merck Sharp and Dohme de Espana, S.A
No definitive cure is known for recurrent, persistent or metastatic cervical carcinoma. Chemotherapy remains the standard of care, although available options are scarce and do not provide satisfactory results. Immune checkpoint inhibitors have shown a strong and prolonged response in several types of cancer, although only in a subset of patients. Defining the profile of the patients likely to benefit from such treatment is a subject of active research. Here, we present a case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatment options and showed a striking response to the immune checkpoint inhibitor pembrolizumab.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据